Related Experiment Video
Updated: Dec 25, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study
Tao Chen1, Di Wu1, Huilong Chen1
1Department and Institute of Infectious Disease, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
Insights
Older age, male sex, and cardiovascular comorbidities increase the risk of death in patients with coronavirus disease 2019 (COVID-19). Common complications include acute respiratory distress syndrome, sepsis, and cardiac injury.
Area of Science:
- Infectious Diseases
- Critical Care Medicine
- Cardiology
Background:
- Coronavirus disease 2019 (COVID-19) is a severe respiratory illness caused by SARS-CoV-2.
- Understanding risk factors and clinical characteristics of fatal COVID-19 cases is crucial for improving patient outcomes.
- Previous studies have highlighted various clinical features, but a detailed analysis of deceased patients is essential.
Purpose of the Study:
- To delineate the clinical characteristics and laboratory findings of patients with COVID-19 who died.
- To identify risk factors and common complications associated with mortality in COVID-19 patients.
Main Methods:
- Retrospective case series analysis of 799 patients diagnosed with COVID-19.
- Data collection from electronic medical records at Tongji Hospital in Wuhan, China, until February 28, 2020.
- Comparison of clinical and laboratory data between deceased patients (n=113) and recovered patients (n=161).
Main Results:
- Deceased patients were significantly older (median 68 years vs. 51 years) and predominantly male (73% vs. 55%).
- Higher prevalence of chronic hypertension (48% vs. 24%) and cardiovascular comorbidities (14% vs. 4%) in deceased patients.
- Common symptoms in deceased patients included dyspnea (62%), chest tightness (49%), and altered consciousness (22%).
- Leukocytosis (50% vs. 4%) and lymphopenia (91% vs. 47%) were more frequent in deceased patients.
- Elevated levels of liver enzymes, cardiac markers, kidney function tests, and D-dimer were observed in non-survivors.
- Frequent complications in deceased patients were ARDS (100%), sepsis (100%), acute cardiac injury (77%), and heart failure (49%).
Conclusions:
- COVID-19 can lead to multi-organ dysfunction, particularly in high-risk individuals.
- Acute respiratory distress syndrome, respiratory failure, sepsis, acute cardiac injury, and heart failure are critical complications.
- Cardiovascular comorbidities are associated with increased risk of cardiac complications and mortality in COVID-19.
Objective:
To delineate the clinical characteristics of patients with coronavirus disease 2019 (covid-19) who died.
Design:
Retrospective case series.
Setting:
Tongji Hospital in Wuhan, China.
Participants:
Among a cohort of 799 patients, 113 who died and 161 who recovered with a diagnosis of covid-19 were analysed. Data were collected until 28 February 2020.
Main Outcome Measures:
Clinical characteristics and laboratory findings were obtained from electronic medical records with data collection forms.
Results:
The median age of deceased patients (68 years) was significantly older than recovered patients (51 years). Male sex was more predominant in deceased patients (83; 73%) than in recovered patients (88; 55%). Chronic hypertension and other cardiovascular comorbidities were more frequent among deceased patients (54 (48%) and 16 (14%)) than recovered patients (39 (24%) and 7 (4%)). Dyspnoea, chest tightness, and disorder of consciousness were more common in deceased patients (70 (62%), 55 (49%), and 25 (22%)) than in recovered patients (50 (31%), 48 (30%), and 1 (1%)). The median time from disease onset to death in deceased patients was 16 (interquartile range 12.0-20.0) days. Leukocytosis was present in 56 (50%) patients who died and 6 (4%) who recovered, and lymphopenia was present in 103 (91%) and 76 (47%) respectively. Concentrations of alanine aminotransferase, aspartate aminotransferase, creatinine, creatine kinase, lactate dehydrogenase, cardiac troponin I, N-terminal pro-brain natriuretic peptide, and D-dimer were markedly higher in deceased patients than in recovered patients. Common complications observed more frequently in deceased patients included acute respiratory distress syndrome (113; 100%), type I respiratory failure (18/35; 51%), sepsis (113; 100%), acute cardiac injury (72/94; 77%), heart failure (41/83; 49%), alkalosis (14/35; 40%), hyperkalaemia (42; 37%), acute kidney injury (28; 25%), and hypoxic encephalopathy (23; 20%). Patients with cardiovascular comorbidity were more likely to develop cardiac complications. Regardless of history of cardiovascular disease, acute cardiac injury and heart failure were more common in deceased patients.
Conclusion:
Severe acute respiratory syndrome coronavirus 2 infection can cause both pulmonary and systemic inflammation, leading to multi-organ dysfunction in patients at high risk. Acute respiratory distress syndrome and respiratory failure, sepsis, acute cardiac injury, and heart failure were the most common critical complications during exacerbation of covid-19.
More Related Videos
Related Concept Videos
COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Acute Respiratory Failure-II
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
Acute Respiratory Failure-I
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Coronary Artery Disease III: Clinical Manifestations
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Acute Respiratory Failure-III

